a high-quality platform, to the attractive United Kingdom ("UK") housing and residential development market. Evergrande has been publicly listed on the Hong Kong Stock Exchange since 2009 with current market capitalization of c. HKD 78 billion and is recognized as the No.1 Chinese real estate developer across multiple segm

rket-leading R&D capabilities, focusing on innovative and first-to-market generic drugs. Sihuan Pharmaceutical has been listed on the Main Board of the Hong Kong Stock Exchange since October 2010. Key Contact NeuroVive Pharmaceutical: Mikael Bronnegard Email: [email protected] Phone No: +46 (0) 70 299 62 64 Steve Campbe

mittee. But in 2009, Duowei was purchased by a Hong Kong businessman* with substantial business interests in China, including two companies listed on the Hong Kong Stock Exchange. The businessman is a founding member of the Tsinghua University Center for US-China Relations and is also fond of writing pro-Beijing essays on Chi